CVRx closes $65m record:
This article was originally published in Clinica
Executive Summary
Hypertension treatment specialist CVRx has received $65m in a fourth round financing led by Johnson & Johnson's venture capital arm, J&J Development (JJD). As part of the financing, Brad Vale, vice president of JJD, has joined Maple Grove, Minnesota-based CVRx's board of directors. The round saw new investor BBT Fund LP combine with existing shareholders New Enterprise, Thomas Weisel, InterWest, ABS, Frazier Healthcare and SightLine to bring the overall financing to in excess of $125m. CVRx will use the funds to advance the current pivotal clinical trials of its Rheos Baroflex hypertension therapy system, which it claims is the only implantable device designed to control hypertension.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.